To ensure the production volumes foreseen in its development plans, AS Olpha, one of the leading pharmaceutical manufacturers in the Baltic region, has purchased and installed new manufacturing equipment worth a total of 4.4 million euros. In total, four new machines have been installed as part of the project, which will significantly increase production capacity, given that in the coming years the company plans to offer at least 50 new generic medicines in European, UK, and other global markets.

This autumn, a new blistering and packaging line was launched, with an investment of more than 2.5 million euros. In addition, a compactor—equipment used for producing dry granulated dosage forms—was installed for 356,750 euros. Another 800,000 euros were invested in the purchase of a new tablet coating drum, and a further 700,000 euros were spent on installing a new capsule-filling machine. The total investment received state support covering 30% of the equipment acquisition costs under the support programme “Large Investment Loan with Capital Rebate,” in cooperation with the Latvian Investment and Development Agency and the Development Finance Institution ALTUM.

“One of our priorities is to achieve greener, more efficient, and more sustainable production processes. Furthermore, as the labour market situation becomes increasingly strained, the automation of production and packaging processes is inevitable. This allows us to ensure the necessary production volumes and efficiency throughout the process. Since our ambition is to continue developing and strengthening pharmaceutical manufacturing in Latvia—an industry with high added value for the national economy and significant export potential—we are making the necessary investments to achieve these goals,” emphasizes Juris Bundulis, Chairman of the Board of AS Olpha.

The new coating drum and capsule-filling machine make it possible to double production capacity. Previously, 42,000 capsules could be produced per hour, while the new capsule-filling machine allows for the production of 84,000.

“Our strategy is built on three core values—sustainability, innovation, and strengthening export capacity. By investing in modern production equipment, green energy, and digitalization, we are strengthening Olpha’s competitiveness and creating significant value for the Latvian economy. At the same time, as a local pharmaceutical manufacturer, we see an opportunity to reduce Latvia’s import dependence by expanding our product portfolio. Currently, 95% of medicines in Latvia are imported, which poses high risks for every patient in cases of supply disruptions. Therefore, Latvia’s pharmaceutical and medicine manufacturing sector must be purposefully developed—no other Baltic country, neither Lithuania nor Estonia, has it at such an advanced level,” stresses J. Bundulis.

It should be added that, according to the company’s long-term development strategy, AS Olpha plans to invest 100 million euros over a five-year period in the development of its product portfolio, modernization of production equipment, capacity expansion for new product launches, and advancement of “green” technological processes. The largest share of the investment will go toward developing new generic medicines and expanding the product portfolio.